Hardik Oncocare
Ambawadi, Ahmedabad, Gujarat
GST No. 24AAIFH1852R1ZY
TrustSEAL Verified
Call 08047642620 87% Response Rate
SEND EMAIL
Product Details:
| Strength | 10 mg/ml |
| Packaging Size | 50 ml |
| Vial Volume | 50 ml |
| Form of Medicine | Injection |
| Gender | Unisex |
| Dose/Strength | 10mg/ml |
| Dosage Form | 500mg |
| Usage | Personal |
Ramucirumab as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
Ramucirumab in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving it.
Ramucirumab, in combination with (irinotecan, folinic acid, and 5-fluorouracil), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.